Ph1/2 study of sacituzumab govitecan in participants with breast cancer
Clinical Trial
A Phase 1/2 Open-label Study of Sacituzumab Govitecan Administered at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer (GS-US-576-7321)